Opterion successfully secures EUR 8.4m Bridge Financing Round

Our portfolio company Opterion Health AG announced today the successful agreement of a EUR 8.4m Bridge Financing
Round. The proceeds from this financing round will be used to complete preclinical activities and prepare for entry into Phase I. Heartfelt congratulations on your success, Opterion!


Press Release_Opterion_Bridge Financing-Round_Final_210119




HEMEX is committed to changing the future of healthcare by guiding the most promising European start-ups through each and every step to bring innovative pharmaceuticals, medical devices and in vitro diagnostics to the market. Headquartered close to the thriving Basel global Life Sciences hub, the goal at HEMEX is to ensure start-ups have access to a wide range of tailored products, practical solutions and fundraising support. This empowers the next generation of transformative discoveries to grow into successful and sustainable businesses, and drive change in both human and animal healthcare. For more information, visit https://hemex.ch/




Leave a Reply

Your email address will not be published. Required fields are marked *